Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà
MedNavigator.ru - Ïîèñê è ïîäáîð ëå÷åíèÿ â Ðîññèè è çà ðóáåæîì
  #1  
Ñòàðûé 30.04.2010, 02:49
Dr.Anisimova Dr.Anisimova âíå ôîðóìà ÂÐÀ×
Ïî÷åòíûé ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 16.01.2007
Ãîðîä: ÐÔ
Ñîîáùåíèé: 14,319
Ñêàçàë(à) ñïàñèáî: 6
Ïîáëàãîäàðèëè 5,347 ðàç(à) çà 4,983 ñîîáùåíèé
Dr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Òðèõîëîãèÿ; +íîâîñòè

Íàø êîëëåãà-òðèõîëîã Âëàäèñëàâ Ïåòðîâè÷ Òêà÷åâ(trichology) ïðåäîñòàâèë ìàòåðèàëû ïî äèàãíîñòèêå â òðèõîëîãèè, êîòîðûå ìîãóò áûòü ïîëåçíû êàê ñïåöèàëèñòàì, òàê è ïàöèåíòàì:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Êîììåíòàðèè ê ñîîáùåíèþ:
DrTatyana îäîáðèë(à): Ñïàñèáî îãðîìíîå!!!
  #2  
Ñòàðûé 17.12.2010, 11:50
Dr.Anisimova Dr.Anisimova âíå ôîðóìà ÂÐÀ×
Ïî÷åòíûé ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 16.01.2007
Ãîðîä: ÐÔ
Ñîîáùåíèé: 14,319
Ñêàçàë(à) ñïàñèáî: 6
Ïîáëàãîäàðèëè 5,347 ðàç(à) çà 4,983 ñîîáùåíèé
Dr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
The International Journal of Trichology (IJT)
- èíäåêñèðóåòñÿ â ÏàáÌåä, äîñòóïíû ïîëíîòåêñòîâûå ñòàòüè, åñòü RSS-ëåíòà
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
- íà äàííûé ìîìåíò íåò îáúåêòèâíûõ îñíîâàíèé äëÿ ðóòèííîãî èñïîëüçîâàíèÿ ìåçîòåðàïèè, òåì áîëåå êàê ìåòîäà ëå÷åíèÿ àëîïåöèè:
Mesotherapy in management of hairloss - Is it of any use?[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Mesotherapy has received a lot of publicity in the media and internet about its possible role in androgenetic alopecia. However, the subject is controversial in view of lack of documented evidence. This article provides a critical commentary on the use of mesotherapy in the management of androgenetic alopecia.
In view of these data, the current position on the use of mesotherapy in pattern hairloss can be summarized as follows:
- Data on its safety and efficacy in pattern hairloss have not been adequately and critically evaluated and documented in proper, peer-reviewed clinical trials.
- Data evaluating the rationale and pharmacology of the combination of herbal and allopathic medicines used are not adequate. There are no clear-cut guidelines on the dosage and efficacy of the products.
- Further, mesotherapy is not entirely a safe technique as publicized in lay media and can give rise to complications, as stated earlier.

Routine use of the technique is therefore not justified. Well-designed controlled scientific studies are required to substantiate the claims of effectiveness of these products. Regulatory authorities and associations have a role to play in ensuring such studies. What is also needed is proper public health education to ensure quality, ethical management and prevention of commercial exploitation of patients.

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Treatment of alopecia areata with 308-nm excimer lamp

Evidence for two independent functional variants for androgenetic alopecia around the androgen receptor gene[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Êîììåíòàðèè ê ñîîáùåíèþ:
step_into îäîáðèë(à): ñïàñèáî!
  #3  
Ñòàðûé 17.12.2010, 12:21
Dr.Anisimova Dr.Anisimova âíå ôîðóìà ÂÐÀ×
Ïî÷åòíûé ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 16.01.2007
Ãîðîä: ÐÔ
Ñîîáùåíèé: 14,319
Ñêàçàë(à) ñïàñèáî: 6
Ïîáëàãîäàðèëè 5,347 ðàç(à) çà 4,983 ñîîáùåíèé
Dr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Effective treatment of folliculitis decalvans using selected antimicrobial agents
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
"Minocycline is a very effective antimicrobial agent in mild cases, but administration of Rifampicin or Clarythromycin in combination with Minocycline is helpful in moderate or resistant cases. An early treatment of FD, with proper antimicrobials, is important for preventing total destruction of hair follicles leading to scarring alopecia."

Histopathologic profile of alopecia areata in Indian patients
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Monilethrix: One step more on the ladder of cytogenetics
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Essentials of hair care often neglected: Hair cleansing[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Shampoos are a complex formulation of ingredients selected to clean the scalp, as well as beautify the hair. This is a complex task leading to the wide variety of shampoos currently in the market. Selecting the proper shampoo for a patient with a given dermatologic hair disorder means understanding the various ingredient functions and the unique attributes of each shampoo type. This article has presented some fundamental knowledge in this regard.

Endocrinology of hirsutism
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
"Hirsutism may result from various endocrine disorders [Table 1]. Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in premenopausal women (incidence 5 - 10%). [1],[2],[3] It was recognized by the Italian physician Antonio Vallisnerie, in 1721, who reported cystic ovaries in overweight infertile women. In 1921, French physicians Achard and Thiers found some coincidence between diabetes and hyperandrogenism when they coined the term 'femmes a barbe diabetique' (=diabetic women with beard).[4] The first systematic description mentioning amenorrhea, hirsutism, obesity, and polycystic ovaries was published by Irving Stein and Michael Leventhal, American gynecologists, in 1935. The so-called Stein-Leventhal-syndrome is a condition heavily influencing a woman΄s reproductive abilities, as well as metabolic and cardiovascular health. [5]"
In summary, PCOS is a highly frequent and often underestimated disorder in a considerable segment of hirsute women. The complex metabolic and hormonal disturbances require a concomitant interdisciplinary and individualized therapy.

Intralesional steroids for alopecia areata
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Conclusion
ILCs are most suitable for patchy, relatively stable hair loss, of limited extent. This modality is not appropriate in rapidly progressive AA or in alopecia totalis / universalis. ILCs are still the preferred method of treatment for most patients.
Key points
- ILCs preferably triamcinolone acetonide is the first-line therapy for adult patients with less than 50% scalp involvement.
- The preferred concentration for the scalp is 5 mg/mL and for the face and eyebrows it is 2.5 mg/mL.
- BD insulin (1 cc) syringes are a good choice, due to lack of leak between syringe and needle.
- If there is no improvement after six months of treatment, ILCs should be stopped.
- Atrophy can be prevented by avoiding injections that are too great in volume per injected site, too frequent or too superficial.

Diffuse neurofibroma of the scalp presenting as circumscribed alopecic patch
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Monilethrix in pattern distribution in siblings: Diagnosis by trichoscopy
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

The many faces of trichotillomania
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Topical immunotherapy in alopecia areata
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Hair evaluation methods: Merits and demerits
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Êîììåíòàðèè ê ñîîáùåíèþ:
Dr.Volgina îäîáðèë(à): Ñïàñèáî!
  #4  
Ñòàðûé 19.12.2010, 14:40
Dr.Anisimova Dr.Anisimova âíå ôîðóìà ÂÐÀ×
Ïî÷åòíûé ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 16.01.2007
Ãîðîä: ÐÔ
Ñîîáùåíèé: 14,319
Ñêàçàë(à) ñïàñèáî: 6
Ïîáëàãîäàðèëè 5,347 ðàç(à) çà 4,983 ñîîáùåíèé
Dr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Äëÿ ïàöèåíòîâ è íå òîëüêî

×òîáû ïðèíÿòü âåðíîå äëÿ ñåáÿ ðåøåíèå â ïëàíå íåîáõîäèìîñòè ëå÷åíèÿ â ïðèíöèïå, âûáîðà ìåòîäà è ò.ä., ëåêàðñòâà, àëüòåðíàòèâíûå/ êîñìåòè÷åñêèå ìåòîäû, ëó÷øå âëàäåòü ìàêñèìàëüíî âîçìîæíî òî÷íîé èíôîðìàöèåé.  ñîâðåìåííîé ìåäèöèíå, åñëè ðàññìàòðèâàòü òðèõîëîãèþ ñ ïîçèöèè èìåííî ìåäèöèíû, íå òîëüêî êàê ïðèíÿòî êîììåðöèè-êîñìåòîëîãèè, èìåþòñÿ âîçìîæíîñòè äëÿ âûÿâëåíèÿ òàêîé èíôîðìàöèè (íàêîïëåííûé è îáðàáîòàííûé îïûò ìíîãî÷èñëåííûõ êà÷åñòâåííûõ èññëåäîâàíèé â ìèðå ïî ëå÷åíèþ äàííûõ ïðîáëåì, äîñòîâåðíîñòü êîòîðûõ îïðåäåëÿåòñÿ îòíîñèòåëüíî îáúåêòèâíî ñ ïîìîùüþ ìàòåìàòè÷åñêîé îáðàáîòêè äàííûõ).
Âàæíûå ìîìåíòû, êîòîðûå ñòîèò ïîÿñíèòü ïîäðîáíåå, íàèáîëåå ðàñïðîñòðàíåííûå ïðîáëåìû - íå áîëåçíè â ïîëíîì ñìûñëå ñëîâà, íî êîñìåòè÷åñêè çíà÷èìûå, ïî êîòîðûì îáðàùàåòñÿ áîëüøèíñòâî ïàöèåíòîâ:
- àíäðîãåíåòè÷åñêàÿ àëîïåöèÿ – ÀÃÀ (èìååòñÿ ââèäó íå òîëüêî âûïàäåíèå âîëîñ, à ÷àùå âñåãî èõ ïîðåäåíèå, îñîáåííî ó æåíùèí) â îáùåì çíà÷åíèè îïðåäåëÿåòñÿ ÷óâñòâèòåëüíîñòüþ ðåöåïòîðîâ âîëîñÿíûõ ôîëëèêóëîâ ê àíäðîãåíàì.  òîé èëè èíîé ñòåïåíè, íî êàæäûé ÷åëîâåê èìååò ïðîÿâëåíèÿ òàêîé ÷óâñòâèòåëüíîñòè ïðàêòè÷åñêè áåç èñêëþ÷åíèÿ. Âûðàæåííîñòü êëèíè÷åñêàÿ, (òî, ÷òî âèäíî âíåøíå, ëèáî ñ ïîìîùüþ ìåòîäîâ èññëåäîâàíèÿ), îïðåäåëÿåòñÿ áîëüøå èíäèâèäóàëüíûìè ãåíåòè÷åñêèìè îñîáåííîñòÿìè. Äëÿ áîëüøèíñòâà ìóæ÷èí â ñèëó íîðìû ÀÃÀ-ýòî ôèçèîëîãè÷íî, íî ïðîÿâëåíèÿ, ñòåïåíü ïðîãðåññèè áóäåò ó âñåõ ðàçíàÿ, ÷òî ïðåèìóùåñòâåííî îïðåäåëÿåòñÿ ãåíåòèêîé(ïîëèãåííûå ïðîÿâëåíèÿ, ñâÿçàííûå ñî ìíîãèìè ãåíàìè, ïîýòîìó íå â êàæäîì ïîêîëåíèè òàêåè ïðîÿâëåíèÿ áóäóò îäèíàêîâû). Ó ìóæ÷èí â ñèëó «ïðèðîäû» ïðîÿâëåíèÿ áîëåå âûðàæåííûå - êëàññè÷åñêàÿ ÀÃÀ, ó æåíùèí â ìåíüøåé ñòåïåíè - â áîëüøèíñòâå ñëó÷àåâ êàê ïîðåäåíèå âîëîñ ñ âîçðàñòîì, ðåæå ïî "ìóæñêîìó òèïó"(êëàññè÷åñêàÿ ÀÃÀ) ñ âûðàæåííûì ïðîãðåññîì, çíà÷èòåëüíûìè êëèíè÷åñêèì ïðîÿâëåíèåì-óæå íå ïðîñòî ïîðåäåíèå, à îáëûñåíèå. Äëÿ æåíùèí ñèòóàöèÿ ïî ñóòè ñ íåêîòîðûìè îòëè÷èÿìè, (íàëè÷èå ðåöåïòîðîâ), òàêàÿ æå ïî ìåõàíèçìó ðàçâèòèÿ: òàêæå ó æåíùèí èìåþòñÿ âîëîñÿíûå ôîëëèêóëû, òàêæå íåêîòîðûå èç íèõ (ïðåèìóùåñòâåííî èç àíäðîãåíçàâèñèìîé îáëàñòè), ÷àñòî íå òîëüêî ëîêàëèçàöèåé â àíäðîãåíçàâèñèìîé çîíå, íî è äèôôóçíî, ÷óâñòâèòåëüíû ê àíäðîãåíàì, íî ïðîÿâëåíèÿ â áîëüøèíñòâå ñëó÷àåâ äëÿ æåíùèí áîëåå «ìÿãêèå», è ïîñòåïåííî çà ìíîãèå ãîäû-äåñÿòèëåòèÿ ê 40-50 ãîäàì îòìå÷àåòñÿ ïîðåäåíèå âîëîñ, êîñìåòè÷åñêè òàêèå ñèòóàöèè áëàãîïðèÿòíû, áîëåå çàìåòíû òàêèå ïðîÿâëåíèÿ òàêæå â îáëàñòè ìàêóøêè, òåìåííîé îáëàñòè - òàêèå ïðîÿâëåíèÿ íàçûâàþò «ïîðåäåíèå âîëîñ ïî æåíñêîìó òèïó»(FEMALE PATTERN HAIR LOSS).
Åñëè âîëîñ ãóñòîé (îò ïðèðîäû ãåíåòè÷åñêè íà ïëîùàäü ïëîòíîñòü âîëîñ âûøå), ýòî åùå ìåíåå çàìåòíî, íî â ëþáîì ñëó÷àå ïðîèñõîäèò ó âñåõ. Ó ëþäåé, ó êîòîðûõ ñ äåòñòâà äèàìåòð âîëîñà íåáîëüøîé îòíîñèòåëüíî - âîëîñ òîíêèé, ìåíüøå ïëîòíîñòü íà åäèíèöó ïëîùàäè, êîñìåòè÷åñêè ýòî áîëåå çàìåòíî, ïîýòîìó òàêèå ïàöèåíòû ïðîñòî îáðàùàþòñÿ ðàíüøå è ÷àùå, ñ ãóñòûì âîëîñîì ïîçæå. Ïî ñóòè âîçíèêíîâåíèÿ ýòî ÀÃÀ, íî òåðìèíà àíäðîãåíçàâèñèìàÿ àëîïåöèÿ ñòàðàþòñÿ èçáåãàòü ó æåíùèí, ÷òîáû îòìåòèòü áîëåå áëàãîïðèÿòíûé ïðîãíîç, ÷òî ýòî ïîñòåïåííûå ìíîãîëåòíèå «âîçðàñòíûå èçìåíåíèÿ», (â òîì ÷èñëå áîëåå ÿâíûå áëèæå ê ìåíîïàóçå, ïî ìåðå âîçðàñòà ìåíÿåòñÿ ñîîòíîøåíèå ýñòðîãåíû-àíäðîãåíû), ÷òî ýòî íå ñòîëüêî «îáëûñåíèå» ñêîëüêî ïîðåäåíèå, äëÿ ìíîãèõ êîñìåòè÷åñêè ïðèåìëåìîå ñîñòîÿíèå. Äëÿ æåíùèí ìîæíî äèàãíîç ÀÃÀ â ýòîì ñëó÷àå ôîðìóëèðîâàòü êàê «ëåãêàÿ» ôèçèîëîãè÷íàÿ ñòåïåíü ïðîÿâëåíèé, åñëè â äèíàìèêå òå÷åíèå ïîñòåïåííîå, íåò ðåçêîãî ïðîãðåññà, íåò îáëàñòè îáëûñåíèÿ, èëè åùå ëó÷øå «ïîðåäåíèå âîëîñ ïî æåíñêîìó òèïó». Ïðè ýòîì ìîæåò îòìå÷àòüñÿ ñåáîðåÿ (ñàëüíûå æåëåçû òàêæå èìåþò ðåöåïòîðû ê àíäðîãåíàì, àêíå, ëèáî íà äàííîå âðåìÿ, ëèáî â ïðîøëîì â âîçðàñòå 15-20 ëåò).

- ðåàêòèâíàÿ äèôôóçíàÿ àëîïåöèÿ (òåëîãåíîâàÿ) - òàêæå ôèçèîëîãè÷íàÿ ðåàêöèÿ, êîíå÷íî êîñìåòè÷åñêè çíà÷èìàÿ, íå áîëåçíü, à ðåàêöèÿ íà êàêîé-ëèáî ñòðåññîâûé ôàêòîð äëÿ öèêëà ðîñòà âîëîñ, âðåìåííàÿ, ò.å. âîññòàíîâëåíèå âîëîñ ïðîèñõîäèò ïðè óñòðàíåíèè ïðè÷èííîãî ôàêòîðà, ÷àùå âñåãî ýòî ïðîèñõîäèò íåçàâèñèìî îò ëå÷åíèÿ
- ó æåíùèí, êîãäà èìåííî îòìå÷àþò âûïàäåíèå è îáðàùàþòñÿ, îáû÷íî îáà âàðèàíòà ñî÷åòàþòñÿ: ò.å. ïîñòåïåííî ñ âîçðàñòîì ðàçâèâàþùååñÿ ïîðåäåíèå â àíäðîãåíçàâèñèìûõ âîëîñÿíûõ ôîëëèêóëàõ,+ïåðèîäû ïåðèîäè÷åñêè ðåàêòèâíîãî âûïàäåíèÿ íà ñàìûå ðàçëè÷íûå ôàêòîðû (ñòðåññ, áåðåìåííîñòü, àáîðò, ðîäû, ïðèåì ëåêàðñòâ, ïîâûøåíèå òåìïåðàòóðû, ñîïóòñòâóþùèå çàáîëåâàíèÿ, îïåðàöèÿ, íàðêîç è ò.ä.-ïðè÷èí ìíîãî)
- ðåàêòèâíàÿ àëîïåöèÿ ïðîõîäèò áåç âìåøàòåëüñòâà â áîëüøèíñòâå ñëó÷àåâ ÷åðåç 5-6ìåñ., îäíàêî æåëàòåëüíî èñêëþ÷èòü ôàêòîðû, êîòîðûå ìîãóò ñïîñîáñòâîâàòü, ëèáî ïðîäëèòü âûïàäåíèå-æåëåçîäåôèöèò, îñîáåííî æåëåçîäåôèöèòàÿ àíåìèÿ (ãåìîãëîáèí, ôåððèòèí), äåôèöèò öèíêà, ÒÒà (ôóíêöèÿ ùèòîâèäíîé æåëåçû) è äð., åñëè åñòü æàëîáû-èñêëþ÷èòü ñîïóòñòâóþùèå çàáîëåâàíèÿ õðîíè÷åñêèå îñîáåííî, êîòîðûå ìîãóò ñïîñîáñòâîâàòü äëèòåëüíîìó âûïàäåíèþ âîëîñ
- ïîýòîìó ñíà÷àëà ðåêîìåíäóåòñÿ íàáëþäåíèå â òå÷åíèå 6 ìåñ.+ñêðèíèíã íà ïåðå÷èñëåííûå âûøå ïðîáëåìû ñ ó÷åòîì æàëîá, åñëè åñòü (ïî ãèíåêîëîãèè/ýíäîêðèíîëîãèè-òîãäà ëó÷øå+êîíñóëüòàöèÿ ãèíåêîëîãà/ýíäîêðèíîëîãà, ÆÊÒ-æàëîáû ïî æåëóäî÷íî-êèøå÷íîìó òðàêòó-òîãäà èññëåäîâàíèå â ýòîé îáëàñòè), åñëè ïîðåäåíèå ïðîäîëæàåòñÿ áîëåå 6 ìåñ.-ëó÷øå ïðîâåñòè îáúåêòèâíûå ìåòîäû èññëåäîâàíèÿ (òðèõîñêîïèÿ, ôîòîòðèõîãðàììà), â òîì ÷èñëå è ïåðåä ïëàíèðóåìûì ëå÷åíèåì
- åñòü ëå÷åíèå êëàññè÷åñêîå ñòàíäàðòíîå, ò.å. òî, ýôôåêòèâíîñòü êîòîðîãî ïðîâåðåíà ïî ðåçóëüòàòàì ìàñøòàáíûõ êà÷åñòâåííûõ èññëåäîâàíèé (îáû÷íî îäíî è òîæå âî âñåì ìèðå, îñîáåííî â ðàçâèòûõ ñòðàíàõ ñ êà÷åñòâåííîé ìåä.ïîìîùüþ), êîãäà ïðåïàðàòû èññëåäîâàíû, êîíå÷íî âûÿâëåíû è ñ ãîäàìè íàêîïèëèñü äàííûå îá ýôôåêòèâíîñòè, î ïîáî÷íûõ ýôôåêòàõ, ïðîòèâîïîêàçàíèÿõ è ò.ä., ïîýòîìó ñ òàêèì ëå÷åíèåì ëó÷øå íå ñïåøèòü ïîêà íå ðàçîáðàëèñü âî âñåé èíôîðìàöèè, íà ýòî âðåìÿ ìîæíî èñïîëüçîâàòü äàæå êîñìåòè÷åñêèå ñðåäñòâà, íî åñëè ó ñåáÿ Âû ÷åòêî óñòàíîâèëè ìîòèâàöèþ(à ýòî åùå âîïðîñ íàñêîëüêî çíà÷èìà ïðîáëåìà íà ñàìîì äåëå, ÷òîáû ïîíÿòü òî÷íî â ñàìîì ñåáå, íà ýòî óõîäèò âðåìÿ) íà ñåðüåçíîå ëåêàðñòâåííîå ëå÷åíèå, òîãäà è ê äåëó ñòîèò ïîäîéòè ãðàìîòíî: ìåòîäû èññëåäîâàíèÿ ñîîòâåòñòâóþùèå, êîíòðîëü çà ëå÷åíèåì ñïåöèàëèñòà, ó÷åò âñåõ äàííûõ ïî ïîêàçàíèÿì, ïðîòèâîïîêààíèÿì, ïîáî÷íûì ýôôåêòàì.
- åñòü âàðèàíòû àëüòåðíàòèâíîé, îáû÷íî êîñìåòè÷åñêîé ïîìîùè, êîòîðûå äîïóñòèìî èñïîëüçîâàòü, îäíàêî î íèõ îáû÷íî íåäîñòàòî÷íî èíôîðìàöèè ïî ïîäòâåðæäåííîé ýôôåêòèâíîñòè è áåçîïàñíîñòè; êàê âàðèàíò, èñïîëüçîâàíèå ïîêà íå ðåøèëèñü íà êëàññè÷åñêîå ëå÷åíèå, ëèáî íå ðåøèëè äëÿ ñåáÿ, ÷òî êëàññè÷åñêîå ñòàíäàðòíîå ëå÷åíèå Âàì íåîáõîäèìî íà äàííûé ìîìåíò
- ñòàíäàðòíûå âàðèàíòû ìîæíî óçíàòü ó âëàäåþùèõ ñîâðåìåííîé äîêàçàòåëüíîé èíôîðìàöèåé ñïåöèàëèñòîâ-òðèõîëîãîâ, òàêæå â Èíòåðíåòå åñòü êà÷åñòâåííûå èñòî÷íèêè, íàïðèìåð, ðàçäåë «àëîïåöèÿ» íà ÄÊ ÐÌÑ(â òîì ÷èñëå ïî äðóãèì îáëàñòÿì ìåäèöèíû, ðóññêèõ èñòî÷íèêîâ êðàéíå ìàëî), òàêæå ïåðåâîäèì ïîñëåäíèå íîâîñòè â ìèðå ïî ïðîáëåìàì+èíîñòðàííûå èñòî÷íèêè:
http://forums.rusmedserv.com/forumdisplay.php?f=11
ÀÃÀ äëÿ ìóæ÷èí ïîäðîáíåå çäåñü:
http://forums.rusmedserv.com/showthread.php?t=162439
- èíîñòðàííûå äëÿ ñïåöèàëèñòîâ (àíãë., íî â ëå÷åíèè îñíîâíûå íàçâàíèÿ ïðåïàðàòîâ ïîíÿòíû), íàïðèìåð:
- èíôîðìàöèÿ ïî ïðîáëåìå ÀÃÀ (íàïðèìåð, íàðóæíî äëÿ ìóæ÷èí è æåíùèí ìèíîêñèäèë, äëÿ ìóæ÷èí ôèíàñòåðèä, äëÿ æåíùèí-àíòèàíäðîãåíû, íàïðèìåð, êîíòðàöåïòèâû, ëàçåðíàÿ ðàñ÷åñêà) :
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
- ïî ëå÷åíèþ
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
- òåëîãåíîâàÿ äèôôóçíàÿ àëîïåöèÿ:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
  #5  
Ñòàðûé 19.12.2010, 14:49
Dr.Anisimova Dr.Anisimova âíå ôîðóìà ÂÐÀ×
Ïî÷åòíûé ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 16.01.2007
Ãîðîä: ÐÔ
Ñîîáùåíèé: 14,319
Ñêàçàë(à) ñïàñèáî: 6
Ïîáëàãîäàðèëè 5,347 ðàç(à) çà 4,983 ñîîáùåíèé
Dr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
- åñëè ïîêà èíôîðìàöèþ âîñïðèíèìàòü íåïðîñòî, âîçìîæíî èçó÷åíèå àëüòåðíàòèâíûõ âàðèàíòîâ, êîñìåòè÷åñêèå â òîì ÷èñëå:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
- â òîì ÷èñëå íàíîâîëîêíà äëÿ êîìóôëÿæà àëîïåöèè, êîñìåòè÷åñêèå ñðåäñòâà äëÿ óõîäà è êîìôîðòà (áîëüøàÿ ÷àñòü êîñìåòè÷åñêèõ ñðåäñòâ è ïðîöåäóð íå èìååò ïîäòâåðæäåííîé ýôôåêòèâíîñòè â èññëåäîâàíèÿõ, íî ìîæåò èñïîëüçîâàòüñÿ êàê äîïîëíåíèå, äëÿ óäîáñòâà óõîäà, íàïðèìåð, ïðè ñåáîðåå - ïîâûøåííîé æèðíîñòè âîëîñ, êîæè ãîëîâû, äëÿ êîìôîðòà), òå ñðåäñòâà, êîòîðûå ïîòåíöèàëüíî èìåþò èíôîðìàöèþ ïî êàêîìó-ëèáî ýôôåêòó, îáû÷íî, òàê èëè èíà÷å ñîäåðæàò âåùåñòâà «êëàññè÷åñêèõ» ñòàíäàðòíûõ ìåòîäîâ, íàïðèìåð, àëåðàíà ñîäåðæèò ìèíîêñèäèëïîäîáíîå âåùåñòâî (áàëüçàì-ñïðåé), ïîýòîìó ìíîãèìè ñïåöèàëèñòàìè ðåêîìåíäóåòñÿ êàê àëüòåðíàòèâà àïòå÷íîìó ìèíîêñèäèëó – ðåãåéíó, âàæíî ïîíèìàòü, ÷òî òîãäà è ñïîñîá ïðèìåíåíèÿ, îñîáåííîñòè ïðåïàðàòà ïðèìåíèìû è ê êîñìåòè÷åñêîìó ñðåäñòâó, ðàç ïðåäïîëàãàåòñÿ ñîäðåæàíèå ëåêàðñòâåííî-ïîäîáíîãî âåùåñòâà (òå æå ïðàâèëà îòìåíû, äëèòåëüíîãî èñïîëüçîâàíèÿ è ò.ä.), ïîìèìî àëåðàíû, àëüòåðíàòèâà êîñìåòè÷åñêàÿ ðåãåéíó àçåëîìàêñ-3,5 % ìèíîêñèäèë
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
- ýâêàïèë ñàìîñòîÿòåëüíî íå îòìå÷åí çíà÷èòåëüíûìè ýôôåêòàìè ñðåäè ñïåöèàëèñòîâ, èññëåäîâàíèé ìàñøòàáíûõ ïîêà íåò, íî âîçìîæíî åãî èñïîëüçîâàíèå êàê êîñìåòè÷åñêîãî ñðåäñòâà ïîòåíöèàëüíî, ò.å. áîëüøå òåîðåòè÷åñêè èìåþùåãî êàêîé-ëèáî ýôôåêò, ñîâìåñòíî ñ ìèíîêñèäèëîì èëè åìó ïîäîáíûìè âåùåñòâàìè:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
- è ò.ä., äëÿ óõîäà ìîæíî èñïîëüçîâàòü êîñìåòè÷åñêèå ñðåäñòâà äëÿ îáëåã÷åíèÿ óõîäà ïðè ñåáîðåå, ïåðå÷èñëåííûå íà ðåñóðñå òðèõîëîäæè è äð. ðåñóðñàõ, ëèáî ñèñòåìà 4, íàïðèìåð, ëèáî óæå ëåêàðñòâåííûå – ñåðèÿ ôðèäåðì àïòå÷íàÿ-âàðèàíòû äëÿ óõîäà åñòü
- ê êëàññè÷åñêèì âàðèàíòàì îòíîñèòñÿ ðàñ÷åñêà ëàçåðíàÿ, ïîäõîäèò êàê îòíîñèòåëüíî áåçîïàñíûé âàðèàíò, åñëè åñòü ñîìíåíèÿ ïîêà îòíîñèòåëüíî ëåêàðñòâ (ëó÷øå ñîâìåñòíîå ïðèìåíåíèå, íî íà ýòàïå ñáîðà èíôîðìàöèè, ñîìíåíèé, êàê âàðèàíò íà äëèòåëüíîå âðåìÿ)
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
- ìíîãèå èõ ýòèõ ñðåäñòâ ìîæíî íàéòè íà äðóãèõ ðåñóðñàõ è â äðóãèõ ôèðìàõ, íàïðèìåð:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ][Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ][Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] è ò.ä., ðåñóðñîâ ïî êîñìåòè÷åñêèì ñðåäñòâàì ìíîãî
Ïîýòîìó êàæäûé ïðèíèìàåò íàèáîëåå êîìôîðòíûé äëÿ ñåáÿ âàðèàíò, òîò, êîòîðûé ñ÷èòàåò íàèáîëåå âåðíûì íà äàííûé ìîìåíò âðåìåíè, âàæíî ñîáðàòü ñíà÷àëà íàèáîëåå ïîëíóþ è äîñòîâåðíóþ èíôîðìàöèþ. Ñíà÷àëà åñòü ñìûñë îïðåäåëèòüñÿ ñ âîçìîæíûì âèäîì àëîïåöèè, åñòü ëè îáëàñòè âûïàäåíèÿ èëè ïîðåäåíèÿ, ôèçèîëîãè÷íî, ëèáî ïðîáëåìà-áîëåçíü, êàê, íàïðèìåð, àóòîèììóííàÿ î÷àãîâàÿ àëîïåöèÿ; æåëàòåëüíî è ñîáñòâåííîå íàáëþäåíèå çà äèíàìèêîé (òåñòû ìîæíî èñïîëüçîâàòü), öèêë ðîñòà ïðîäîëæèòåëüíûé â íîðìå, è èçìåíåíèÿ ìîãóò äëèòüñÿ êàê ïîðåäåíèå, òàê è âîññòàíîâëåíèÿ, ìåñÿöû, â òîì ÷èñëå è ïðè ëå÷åíèè; òðèõîñêîïèÿ, ôîòîòðèõîãðàììà, îñîáåííî, åñëè ïëàíèðóåòñÿ «êëàññè÷åñêèé» âàðèàíò ëå÷åíèÿ, ÄÎ íà÷àëà è äèíàìèêà êàæäûå 6 ìåñ.-12ìåñ., ò.å. ðàç â ãîä-ïîë-ãîäà, ïðèìåð èññëåäîâàíèÿ:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Ìîãó îòìåòèòü, ÷òî íà êëàññè÷åñêèé âàðèàíò ëå÷åíèÿ èäåò íå òàê ìíîãî ïàöèåíòîâ ïðè ðàçóìíîì ïîäõîäå, òàê êàê ëó÷øå âçâåñèòü «âñå» çà è «ïðîòèâ». Ìíîãèå ðåøàþò, ÷òî êîñìåòè÷åñêèé äåôåêò ïðîáëåìû íå íàñòîëüêî çíà÷èì, ÷òî ýòî íå áîëåçíü (íàïðèìåð, ÀÃÀ, èëè ïîðåäåíèå ïî æåíñêîìó òèïó, ëèáî ðåàêòèâíàÿ âðåìåííàÿ àëîïåöèÿ), ÷òîáû åæåäíåâíî â òå÷åíèå ìíîãèõ ìåñÿöåâ èñïîëüçîâàòü ïðåïàðàòû, ëèáî ïîáî÷íûå ýôôåêòû íå óñòðàèâàþò, ÷àñòü ïàöèåíòîâ ïðèõîäèò ê ìûñëè ïîñëå ìíîãèõ «ìûòàðñòâ» è òðàò íà êîñìåòè÷åñêèå ñðåäñòâà, ïðîöåäóðû ñ ýôôåêòèâíîñòüþ ïîä âîïðîñîì, ÷òî êîñìåòè÷åñêèé äåôåêò äëÿ íèõ èìååò áîëüøîå ïñèõîýìîöèîíàëüíîå çíà÷åíèå è îíè òîãäà óæå èìåþò «ìîòèâ» íà ëå÷åíèå è íàáëþäåíèå. Âîçìîæíî ñîâìåùåíèå ìåòîäîâ. Ïîìîùü êîñìåòîëîãà, èñïîëüçîâàíèÿ êîñìåòè÷åñêèõ ñðåäñòâ, óñëóã ïàðèêìàõåðà î÷åíü âàæíà â ðåøåíèè òàêèõ ïðîáëåì, ÷òîáû, åñëè è íå ïîâëèÿòü ýôôåêòèâíî íà ïðîöåññ âûïàäåíèÿ (ýòî ëó÷øå ðåøàòü ñî ñïåöèàëèñòîì òðèõîëîãîì, åñëè äåéñòâèòåëüíî íóæíî íà íåãî âëèÿòü, ñ ÷åì ñòîèò òîæå îïðåäèëèòüñÿ è ýòî íå òàê ïðîñòî, ñíà÷àëà âñåì ïàöèåíòàì êàæåòñÿ, ÷òî îáÿçàòåëüíî áóäóò "ëå÷èòü" ïðîáëåìó), òî ñäåëàòü áîëåå êîìôîðòíûì óõîä, ïðèåìëèìûì äëÿ ñåáÿ ñâîé âíåøíèé âèä.
Âëèÿíèå íà öèêë ðîñòà âîëîñ, èçìåíåíèå åãî â òó èëè èíóþ ñòîðîíó êîíå÷íî ëó÷øå îñòàâèòü ñïåöèàëèñòàì, âàæíî ïîíèìàòü, ÷òî ýòî òðåáóåò ñïåöèàëüíûõ çíàíèé, òðåáóåò äëèòåëüíîãî âðåìåíè-ìåñÿöû(òàêîé óæ öèêë ðîñòà âîëîñ ïî ïðèðîäå ñâîåé), ÷òî íè øàìïóíè, íè áîëüøèíñòâî êîñìåòè÷åñêèõ ñðåäñòâ áåç ëåêàðñòâåííûõ âåùåñòâ â ñîñòàâå, òåì áîëåå íàíåñåííûå íà íåñêîëüêî ìèíóò, ìåñÿö-äâ-òðè â ãîäó íå ìîãóò âíåñòè òàêèå èçìåíåíèÿ, à òå ïðåïàðàòû, êîòîðûå òàêèå èçìåíåíèÿ âíîñÿò-ëåêàðñòâà, èìåþò ïîñëåäñòâèÿ-ïîìèìî ýôôåêòèâíîñòè åùå è ïîáî÷íûå, åùå è îñîáåííîñòè èñïîëüçîâàíèÿ, äëèòåëüíîñòü ëå÷åíèÿ, íåîáõîäèìîñòü êîíòðîëÿ òðèõîëîãà(òðóä ïàöèåíòà è âðà÷à ñîâìåñòíûé) è íåò îðåîëà ÷óäà.
  #6  
Ñòàðûé 28.12.2010, 16:27
Dr.Anisimova Dr.Anisimova âíå ôîðóìà ÂÐÀ×
Ïî÷åòíûé ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 16.01.2007
Ãîðîä: ÐÔ
Ñîîáùåíèé: 14,319
Ñêàçàë(à) ñïàñèáî: 6
Ïîáëàãîäàðèëè 5,347 ðàç(à) çà 4,983 ñîîáùåíèé
Dr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Minoxidil-Induced Trichostasis Spinulosa of Terminal Hair
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Association of Hearing Loss With PHACE Syndrome
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
PHACE syndrome describes a spectrum of anomalies associated with large facial infantile hemangiomas and characterized by posterior fossa malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities.
Conclusions There is an underrecognized risk of hearing loss in patients with PHACE syndrome, although the exact nature of such deficiencies can vary. Patients with PHACE syndrome who have cutaneous hemangiomas involving the ear should be evaluated for intracranial hemangiomas and monitored for hearing loss. Early detection and therapy of intracranial hemangiomas may slow or stop tumor growth, resultant hearing loss, and structural damage.
  #7  
Ñòàðûé 31.12.2010, 10:56
Dr.Anisimova Dr.Anisimova âíå ôîðóìà ÂÐÀ×
Ïî÷åòíûé ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 16.01.2007
Ãîðîä: ÐÔ
Ñîîáùåíèé: 14,319
Ñêàçàë(à) ñïàñèáî: 6
Ïîáëàãîäàðèëè 5,347 ðàç(à) çà 4,983 ñîîáùåíèé
Dr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Iron Deficiency Not Likely Culprit in Female Hair Loss
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Conclusion
ID is common in women but not increased in patients with FPHL or CTE compared with control subjects.
Limitations
The effect of correction of ID on hair loss is unknown.


Abnormal inner root sheath of the hair follicle in the loose anagen hair syndrome: An ultrastructural study
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]


Involvement of the bulge region with decreased expression of hair follicle stem cell markers in senile female cases of alopecia areata
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]


Repigmentation of hair after latanoprost therapy
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]


Cognitive training with photographs as a new concept in an education campaign for self-detection of melanoma: a pilot study in the community
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]


Genetic factors in contact allergy—review and future goals
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]


A practical, algorithmic approach to diagnosing hair shaft disorders
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]


The significance of anticardiolipin antibody and immunologic abnormality in livedoid vasculitis
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]


Tuberous sclerosis complex: tumors and tumorigenesis
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Cutaneous adverse drug reaction to heparins with hypereosinophilia and high IgE level


Prurigo pigmentosa: a clinicopathological study and analysis of associated factors
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
  #8  
Ñòàðûé 05.03.2011, 14:34
Dr.Anisimova Dr.Anisimova âíå ôîðóìà ÂÐÀ×
Ïî÷åòíûé ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 16.01.2007
Ãîðîä: ÐÔ
Ñîîáùåíèé: 14,319
Ñêàçàë(à) ñïàñèáî: 6
Ïîáëàãîäàðèëè 5,347 ðàç(à) çà 4,983 ñîîáùåíèé
Dr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Male pattern baldness and the risk of prostate cancer(óìåñòíî èñïîëüçîâàíèå ôèíàñòåðèäà â ëå÷åíèè ÀÃÀ)
Conclusions: This study shows an association between early-onset androgenic alopecia and the development of prostate cancer. Whether this population can benefit from routine prostate cancer screening or systematic use of 5-alpha reductase inhibitors as primary prevention remains to be determined.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

- âòîðè÷íàÿ àëîïåöèÿ â ðåçóëüòàòå ïðîâåäåíèÿ ìåçîòåðàïèè:
Alopecia secondary to mesotherapy
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Abstract
Mesotherapy has recently become an advertised method for the treatment of different types of alopecia despite the lack of any data regarding its efficacy and possible side effects. The substances injected into the scalp include "cocktails" of natural plant extracts, homoeopathic agents, vitamins, vasodilators, and drugs that may stimulate hair growth, such as finasteride and minoxidil. We report two cases of patchy alopecia that developed after mesotherapy for the treatment of androgenetic alopecia. In the first patient, alopecia developed after injections of the heparinoid vasodilator mesoglycan; the 3-month follow-up examination revealed a small residual area of cicatricial alopecia. The second patient developed reversible alopecia after multiple scalp injections of homeopathic agents. These cases underline the possible risks of mesotherapy as a therapeutic technique for hair loss.

Êîììåíòàðèè ê ñîîáùåíèþ:
nastassia îäîáðèë(à):
  #9  
Ñòàðûé 05.03.2011, 15:27
Dr.Anisimova Dr.Anisimova âíå ôîðóìà ÂÐÀ×
Ïî÷åòíûé ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 16.01.2007
Ãîðîä: ÐÔ
Ñîîáùåíèé: 14,319
Ñêàçàë(à) ñïàñèáî: 6
Ïîáëàãîäàðèëè 5,347 ðàç(à) çà 4,983 ñîîáùåíèé
Dr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Treatment of female pattern hair loss with the androgen receptor antagonist flutamide
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
- ôëóòàìèä äëÿ ïàöèåíòîê, íå îòâåòèâøèõ íà òåðàïèþ âåðîøïèðîíîì ïðè FPHL

Traction Alopecia in Two Adolescent Sikh Brothers—An Underrecognized Problem Unmasked by Migration
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
  #10  
Ñòàðûé 14.04.2011, 16:38
Dr.Anisimova Dr.Anisimova âíå ôîðóìà ÂÐÀ×
Ïî÷åòíûé ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 16.01.2007
Ãîðîä: ÐÔ
Ñîîáùåíèé: 14,319
Ñêàçàë(à) ñïàñèáî: 6
Ïîáëàãîäàðèëè 5,347 ðàç(à) çà 4,983 ñîîáùåíèé
Dr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Radiation-induced alopecia
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Physiological Changes in Scalp, Facial and Body Hair after the Menopause
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Conclusions This is the first comprehensive study of the subjective hair changes in postmenopausal women. This study demonstrates two distinct patterns of hair change relating to age, which may reflect different underlying pathophysiological mechanisms and are of relevance to the medical management of these women as well as being possible predictors of health outcomes.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

- ïðåïàðàòû äëÿ ëå÷åíèÿ ïîðåäåíèÿ ðåñíèö/áðîâåé, â òîì ÷èñëå ïðè ÃÀ(íàêàïëèâàþòñÿ èññëåäîâàíèÿ)
Bimatoprost in the treatment of eyelash universalis alopecia areata[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Conclusion: Bimatoprost may be effective and safe in the treatment of eyelash AA. 43.24% of the patients had an acceptable cosmetic response (total and moderate growth). Limitations: Design without control.
In December 2008 the US Food and Drug Administration approved 0.03% bimatoprost solution (Latisse® ), identical to the ophthalmic solution for glaucoma treatment (Lumigan® ), for increasing eyelash length, thickness and darkness in patients with hypotrichosis of the eyelashes, [2] or persons who desire lengthy eyelashes.
We observed an acceptable response in 43.24% of patients with bilateral eyelashes AA using 0.03% bimatoprost ophthalmic solution, but we observed three patients with conjunctivitis. The limitations in this study are: we did not compare the treatment with other treatment or placebo, the subjects did not have the same basal situation, this is not a blinded study.

Loose anagen hair syndrome[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Diagnostic Criteria
- proposed diagnostic criteria for LAS on the basis of hair pull test and trichogram:
1.Positive pull test results with painless extraction of at least 10 LAHs.
2.The presence of more than 80% LAH on trichogram.
Conclusions
Loose anagen hair syndrome may sometimes be confused with other hair disorders, but the history, clinical findings and light microscopy of pulled hair should easily exclude other diagnosis. To summarize, some important practical points to remember while treating a child complaining of hair loss are:
1.A high index of suspicion in a child younger than six years
2.A hair pull test and trichogram findings are essential for the diagnosis
3.Spontaneous resolution in most cases, but minoxidil may fasten resolution and may be used in severe cases.

An extraordinary colocalization of alopecia areata and vitiligo[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
  #11  
Ñòàðûé 26.04.2011, 23:42
Dr.Anisimova Dr.Anisimova âíå ôîðóìà ÂÐÀ×
Ïî÷åòíûé ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 16.01.2007
Ãîðîä: ÐÔ
Ñîîáùåíèé: 14,319
Ñêàçàë(à) ñïàñèáî: 6
Ïîáëàãîäàðèëè 5,347 ðàç(à) çà 4,983 ñîîáùåíèé
Dr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Keratosis follicularis spinulosa decalvans in a female
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Keratosis follicularis spinulosa decalvans (KFSD), is a rare follicular syndrome associated with widespread keratosis pilaris and progressive scarring alopecia. This genodermatoses often starts at infancy or early childhood with an X-linked mode of inheritance. Males are predominantly affected and females frequently show no disease or only a mild form. We describe this not so common entity of KFSD in a nine year old female child.

Turban PUVASOL: An effective treatment in alopecia totalis
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Plica neuropathica (Plica polonica) following Azathioprine-induced pancytopenia
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Scarring hair loss linked to grooming practices in African–American women
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Conclusions Our survey results suggest that there is a high prevalence of central hair loss among African American women. Hair styles causing traction as well as inflammation in the form of bacterial infection may be contributing to the development of CCCA. The increase in diabetes mellitus type 2 among those with CCCA is in line with the recent theory that cicatricial alopecia may be a manifestation of metabolic dysregulation.
  #12  
Ñòàðûé 09.06.2011, 13:00
Dr.Anisimova Dr.Anisimova âíå ôîðóìà ÂÐÀ×
Ïî÷åòíûé ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 16.01.2007
Ãîðîä: ÐÔ
Ñîîáùåíèé: 14,319
Ñêàçàë(à) ñïàñèáî: 6
Ïîáëàãîäàðèëè 5,347 ðàç(à) çà 4,983 ñîîáùåíèé
Dr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
- îêðàøèâàíèå âîëîñ êðàñêàìè, ñîäåðæàùèìè ïàðàôåíèëåíäèàìèí ìîæåò áûòü íåáåçîïàñíûì:
Severe Hair Loss of the Scalp due to a Hair Dye Containing Para phenylenediamine
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Many cases of dermatitis due to hair dye may be overlooked, but severe dermatitis may sometimes last for more than 3 weeks [5]. Therefore, dermatologists need to pay more attention to hair dye allergies.
- ïðèìåð ñîâðåìåííîãî âàðèàíòà òðàíñïëàíòàöèè âîëîñ ñ èñïîëüçîâàíèåì ôîëëèêóëÿðíûõ ãðàôòîâ:
Micropunch (0.8*mm or Less in Diameter) Hair Transplantation
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
  #13  
Ñòàðûé 15.06.2011, 23:11
Dr.Anisimova Dr.Anisimova âíå ôîðóìà ÂÐÀ×
Ïî÷åòíûé ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 16.01.2007
Ãîðîä: ÐÔ
Ñîîáùåíèé: 14,319
Ñêàçàë(à) ñïàñèáî: 6
Ïîáëàãîäàðèëè 5,347 ðàç(à) çà 4,983 ñîîáùåíèé
Dr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
- ïîæàëóé, ïîäò÷åðêèâàåò ëèøíèé ðàç, ÷òî "ïîï-èññëåäîâàíèå" ñïåêòðàëüíûé àíàëèç íóæåí êàê ðåäêîå èñêëþ÷åíèå äëÿ äèàãíîñòèêè èíòîêñèêàöèé, íàêîïëåíèÿ òÿæåëûõ ìåòàëëîâ è ò.ä.:
Surprising hair analysis results following acute carbofuran intoxication
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ].

- òðèõîñêîïèÿ, ñòàòüÿ íå íîâàÿ, íî ïðîñòàÿ
Trichoscopy for common hair loss diseases:
Algorithmic method for diagnosis
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
  #14  
Ñòàðûé 28.06.2011, 02:34
Dr.Anisimova Dr.Anisimova âíå ôîðóìà ÂÐÀ×
Ïî÷åòíûé ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 16.01.2007
Ãîðîä: ÐÔ
Ñîîáùåíèé: 14,319
Ñêàçàë(à) ñïàñèáî: 6
Ïîáëàãîäàðèëè 5,347 ðàç(à) çà 4,983 ñîîáùåíèé
Dr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
- õîðîøèé øàìïóíü, äà íå íàø("êëîáåêñ", "clobex", íåêîòîðûì ïàöèåíòàì ñ ïñîðèàçîì âîëîñ. ÷àñòè ãîëîâû õîòÿ áû, óäàåòñÿ çàêàçàòü)
Efficacious and safe management of moderate to severe scalp seborrhoeic dermatitis using clobetasol propionate shampoo 0·05% combined with ketoconazole shampoo 2%: a randomized, controlled study
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

The International Journal of Trichology (IJT)
- "ïåðõîòü"
A new postulate on two stages of dandruff: A clinical perspective
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Clinical photography for trichology practice: Tips and tricks
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Randomized comparison of topical betamethasone valerate foam, intralesional triamcinolone acetonide and tacrolimus ointment in management of localized alopecia areata
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Conclusion: Intralesional triamcinolone acetonide is the best, betamethasone valerate foam is better than tacrolimus in management of localized AA.

Graham-Little Piccardi Lassueur syndrome: An unusual variant of follicular lichen planus
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Graham Little-Piccardi-Lassueur syndrome is a type of lichen planopilaris (follicular lichen planus) characterized by the triad of patchy cicatricial alopecia of the scalp, noncicatricial alopecia of the axilla and groin, and a follicular spinous papule on the body, scalp, or both. It is four times more common in females in the age group of 30-70 years. Only a few cases have been reported in literature wherein the disease has affected males. Herein we report a young male who presented with features of Graham Little-Piccardi-Lassueur syndrome.

Malherbe's calcifying epithelioma (pilomatrixoma): An uncommon periocular tumor
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Localised acquired trichorrhexis nodosa of the scalp hair induced by a specific comb and combing habit - A report of three cases
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Trichorrhexis nodosa is a hair shaft disorder often encountered in clinical practice. Acquired trichorrhexis is commoner of the two types and is most often due to weathering from physical or chemical causes. We report three representative cases of localized acquired trichorrhexis encountered in our clinic attributable to a specific comb, used commonly in Kerala, a Southern state of India.

Hypertrichosis due to congenital hypothyroidism
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
In conclusion, we suggest that full assessment of thyroid function be carried out in all cases of hypertrichosis or abnormal distribution of body hair.

Congenital triangular alopecia: A close mimicker of alopecia areata
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Alopecia areata - probing the deforestation
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
A variety of treatment options such as phototoxic psoralen and ultraviolet-A therapy after topical application of 0.1% 8-methoxypsoralen, diphencyprone, dinitrochlorobenzene, squaric acid dibutylester, steroids, minoxidil, anthralin, and bexarotene have shown promise in managing AA.

Light microscopy of the hair: A simple tool to "untangle" hair disorders
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Sebaceous gland loss and inflammation in scarring alopecia: A*potential role in pathogenesis.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Conclusions
This study demonstrates that sebaceous gland loss is a common and early finding among SA. In addition, sebaceous gland and/or duct inflammation may play a role in initiating or accelerating follicular damage during the development of SA.

Isoniazid-induced alopecia
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Isoniazid is a safe and very effective antituberculosis drug. Antimitotic agents routinely cause alopecia. Drug-induced alopecia is usually reversible upon withdrawal of the drug. Isoniazid, thiacetazone and ethionamide are the antituberculosis drugs which have been associated with alopecia. Isoniazid-induced alopecia was observed in one case and confirmed by the finding that hair growth resumed when drug removed from the regimen.

CONFOCAL MICROSCOPIC FEATURES OF SCARRING ALOPECIA: PRELIMINARY REPORT
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Conclusion: in our preliminary study it seems to be evident the effective usefulness of RCM for scarring alopecias diagnosis and follow-up. Moreover, RCM seems to be also promising for differential diagnosis between the different entities.

Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: An update of what we now know
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
The role of genetic predisposition and the influence of sex steroid hormones are indisputable to the pathogenesis of male androgenetic alopecia (MAGA). The role of sex steroid hormones in female pattern hair loss (FPHL) is less known. A good knowledge of the pathophysiology underlying MAGA and FPHL empowers the clinician to confidently counsel patients and make informed therapeutic decisions. Vigorous research in recent years has provided greater insight into the role of genetics and sex steroids in physiological hair growth and cycling, as well as in hair follicle miniaturization, the histological hallmark of MAGA and FPHL. In the present review article directed towards clinicians, we discuss the current understanding of the role of androgens and oestrogens, as well as genetic associations with MAGA and FPHL. We also briefly discuss the interpretation of direct-to-consumer genetic testing for baldness to help clinicians understand the limitations of such tests.
MAGA and FPHL are distinct clinical entities with overlap in some underlying biomolecular mechanisms that lead to histologically indistinguishable hair follicle miniaturization. Genetic predisposition and sex steroid hormones are prerequisites to both conditions, although their full genetic risk profiles and the role of androgens and oestrogens in both conditions remain to be more accurately defined through further research work. Decoding of the full genetic risk profile of baldness is not unforeseeable with rapidly expanding large-scale genotyping technology, which makes pharmacogenetic risk profiling for the individualization of baldness treatments a possible goal.

Is atopy and autoimmunity more prevalent in patients with alopecia areata? A comparative study
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Conclusion The frequencies of autoimmune and atopic diseases were not different between adult and paediatric patients and the control group. We did not find a statistically significance between disease severity and personal and family history of autoimmune disease in the two groups. Disease severity was not related to nail changes in the adult group. However, severe alopecia areata was more prevalent in children with nail changes. Furthermore, ophiasis pattern was more prevalent in the paediatric group with nail changes compared with the adult group.

- ìèíîêñèäèë/ðåãåéí 5% ïåíà 1 ðàç â äåíü ñîïîñòàâèìà ñ 2-õ êðàòíûì èñïîëüçîâàíèåì îáû÷íîãî 2% ðåãåéíà ó æåíùèí(ÀÃÀ)
A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Conclusions
Once-daily 5% MTF is noninferior and as effective for stimulating hair growth as twice-daily 2% MTS in women with androgenetic alopecia and is associated with several aesthetic and practical advantages.

Lichenoid red tatoo reaction and alopecia areata
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Specular light reflectance of flakes in seborrhoeic dermatitis of the scalp: a pilot study
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Evidence of increased DNA methylation of the androgen receptor gene in occipital hair follicles from men with androgenetic alopecia
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
  #15  
Ñòàðûé 29.07.2011, 23:08
Dr.Anisimova Dr.Anisimova âíå ôîðóìà ÂÐÀ×
Ïî÷åòíûé ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 16.01.2007
Ãîðîä: ÐÔ
Ñîîáùåíèé: 14,319
Ñêàçàë(à) ñïàñèáî: 6
Ïîáëàãîäàðèëè 5,347 ðàç(à) çà 4,983 ñîîáùåíèé
Dr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Investigative guidelines for alopecia areata
Article first published online: 20 JUN 2011
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
The reported efficacy of various treatments for alopecia is difficult to compare based on a general lack of consideration in case reports/series and clinical trials of the spontaneous regrowth or baseline prognostic factors seen in alopecia areata and a general lack of quantification of hair growth. This report will give both the investigator and clinician guidelines for clinical trial design that will take into account variables known to effect efficacy results such as baseline severity, pattern, and duration of hair loss, age of the subject, and concomitant conditions that may impact on potential regrowth. Reliable methods of assessment of efficacy and response criteria that will enable direct comparison of results between agents will also be discussed.

Cardiomyopathy with Alopecia and Palmoplantar Keratoderma (CAPK) is caused by a JUP mutation
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

linical profile and impact on quality of life: Seven years experience with patients of alopecia areata
linical profile and impact on quality of life: Seven years experience with patients of alopecia areata
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Brain-derived nerve factor and neurotrophins in androgenetic alopecia.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Conclusions: Neurotrophic factors, especially BDNF, may be important in mediating the effects of androgens on hair follicles, serving as a negative regulatory control signal. Further studies may lead to novel pharmacologic interventions in AGA.

Alteration in Hair Texture Following Regrowth in Alopecia Areata
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Conclusions* The precipitating factor for a change in hair texture in alopecia areata may be a result of treatment, pathophysiologic changes, or a combination of both. Whether the change is triggered at the level of stem cell differentiation, by cytokine or hormonal influences, gene expression during hair follicle development, a combination of all of these, or an unknown cause is a question that remains to be answered.

Alopecia areata: a new treatment plan
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
(ñòàòüþ ìîæíî ñêà÷àòü ïîëíîñòüþ)

Alopecia: evaluation and treatment
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Randomized, double-blind, split-side comparison study of moisturizer containing licochalcone vs. 1% hydrocortisone in the treatment of infantile seborrhoeic dermatitis
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Conclusion Moisturizer containing 0.025% licochalcone had higher cure rate compared to 1% hydrocortisone for the treatment of ISD at day 3–4. However, by the end of the first week, this difference was no longer significant.
Çàêðûòàÿ òåìà


Îïöèè òåìû Ïîèñê â ýòîé òåìå
Ïîèñê â ýòîé òåìå:

Ðàñøèðåííûé ïîèñê
Îïöèè ïðîñìîòðà

Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 23:09.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.